// App-Quantinova.ai

Abstract 11276 : Safety and Tolerability of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients During Sodium Depletion or Irbesartan Coadministration

Researchers

Presenter

  • Stephen Huang

Principal Investigators

  • Jorg Taubel

  • Akshay S Desai

  • Yansong Cheng

  • Bahru Habtemariam

Medical Centers

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • Wayland, MA

  • Merrimack Pharmaceuticals, Cambridge, MA

  • RICHMOND RESEARCH INSTITUTE, London

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Angiotensinogen

  • Sex hormone binding globulin

Drug/Treatment

  • Angiotensin II

  • Irbesartan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved